www.apeiron-biologics.com
Evotec and Apeiron Biologics to Discover Novel Pain Therapeutics
Apeiron Biologics GmbH entered into a discovery collaboration with Evotec to develop small molecules targeting a novel therapeutic concept for pain relief. This concept is based on research activities of Prof. Josef Penninger, Director of the Institute for Molecular Biotechnology of the Austrian Academy of Sciences (IMBA).
During the initial phase of this collaboration, Apeiron Biologics and Evotec will jointly develop tailored biochemical and cellular assays, and Evotec will apply its outstanding skills in utilising such assays for ultra-high throughput screening to identify promising hit molecules. At a later stage, both companies aim at advancing a selected lead compound into preclinical development up to proof-of-concept in patients. Commercialisation rights which are shared equally may be out-licensed or assigned to a Pharma partner.
"To establish strategic partnerships with renowned Pharma partners such as Evotec is an important step in Apeiron's development and the validation of the Company's business model. This collaboration is of key importance for this scientifically and commercially highly interesting project in pain. We are looking forward to an enjoyable and rewarding collaborative effort."
Dr Hans Loibner, Chief Executive Officer, Apeiron Biologics